IMAGIN Medical

Investor Center

Corporate Profile

Imagin Medical, a surgical imaging company, is focusing on bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common cancer in men. It is the most expensive form of cancer to treat over the lifetime of a patient because the cancer will return in more than 50% of cases. Approximately 600,000 people are living with that fear in the U.S. today. It is estimated that in 2021, 83,000 new cases of bladder cancer will be diagnosed, and more than 17,000 deaths will occur.*

*https://seer.cancer.gov/statfacts/html/urinb.html

Corporate Presentation

Investor Presentation - Q4 2021, Visualizing Cancer in a Different Light.

IMEXF, IME

Recent News

26 August 2021 in Investor Center

IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing

Rapha Capital BioVentures Fund I, LP (RCBVFI), Leads New Convertible Note Financing Kevin Slawin, MD, a Leading UroOncologist and Manager of RCBVFI Joins the Board Imagin Medical’s i/Blue™ Imaging System is…
Read More
18 August 2021 in Investor Center

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final…
Read More
17 August 2021 in Investor Center

Imagin Medical Reports Company on Schedule for American Urology Association Demonstration

Vancouver, B.C. and Boston, MA, August 17, 2021 – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported that the final…
Read More